K. D. Gonzalez et al., “Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families with p53 Germline Mutations,” Journal of Clinical Oncology 27, no. 8 (2009): 1250–1256.
P. D. Pharoah, P. Guilford, and C. Caldas, “Incidence of Gastric Cancer and Breast Cancer in CDH1 (E-cadherin) Mutation Carriers from Hereditary Diffuse Gastric Cancer Families,” Gastroenterology 121, no. 6 (2001): 1348–1353.
M. K. Schmidt et al., “Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2* 1100delC Germline Mutation,” Journal of Clinical Oncology 25, no. 1 (2006): 64–69.
M. K. Schmidt et al., “Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2* 1100delC Germline Mutation,” Journal of Clinical Oncology 25, no. 1 (2006): 64–69.
B. Zhang et al., “Genetic Variants Associated with Breast-Cancer Risk: Comprehensive Research Synopsis, Meta-analysis, and Epidemiological Evidence,” The Lancet Oncology 12, no. 5 (May 2011): 477–488.
D. F. Easton et al., “Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk,” New England Journal of Medicine 372, no. 23 (2015): 2243–2257.
A. Broeks et al., “Identification of Women with an Increased Risk of Developing Radiation-Induced Breast Cancer: A Case Only Study,” Breast Cancer Research 9, no. 2 (2007): R26.
A. Broeks et al., “Identification of Women with an Increased Risk of Developing Radiation-Induced Breast Cancer: A Case Only Study,” Breast Cancer Research 9, no. 2 (2007): R26.
F. J. Couch et al., “Inherited Mutations in 17 Breast Cancer Susceptibility Genes among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer,” Journal of Clinical Oncology 33, no. 4 (2015): 304–311.
К сожалению, в нашей стране подобного закона еще не принято.
National Comprehensive Cancer Network, “Genetic/Familial High-Risk Assessment: Breast and Ovarian,” NCCN Clinical Practice Guidelines in Oncology, открыто 19 августа 2017 года, https://www.tri-kobe.org/nccn/guideline/gynecological/english/genetic_familial.pdf.
C. K. Kuhl et al., “Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer,” Journal of Clinical Oncology 23, no. 33 (2005): 8469–8476.
S. Iodice et al., “Oral Contraceptives and Breast or Ovarian Cancer Risk in BRCA 1/2 Carriers: A Meta-analysis,” European Journal of Cancer 46, no. 12 (August 2010): 2275–2284. Глава седьмая. Лекарства и операции, которые стоит рассмотреть
J. Cuzick et al., “Preventive Therapy for Breast Cancer: A Consensus Statement,” The Lancet Oncology 12, no. 5 (2011): 496–503.
P. E. Goss et al., “Exemestane for Breast-Cancer Prevention in Postmenopausal Women,” New England Journal of Medicine 364, no. 25 (2011): 2381–2391.
J. Cuzick et al., “Anastrozole for Prevention of Breast Cancer in High-Risk Postmenopausal Women (IBIS-II): An International, Double-Blind, Randomised Placebo-Controlled Trial,” The Lancet 383, no. 9922 (2014): 1041–1048.
L. E. Rutqvist et al., “Contralateral Primary Tumors in Breast Cancer Patients in a Randomized Trial of Adjuvant Tamoxifen Therapy,” Journal of the National Cancer Institute 83: 1299–1306.
B. Fisher et al., “Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study,” Journal of the National Cancer Institute 90, no. 18 (September 1998): 1371–1388.
J. Cuzick et al., “Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer,” Journal of the National Cancer Institute 96, no. 8 (April 2004): 621–628.
M. C. King et al.,“Tamoxifen and Breast Cancer Incidence among Women with Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial,” Journal of the American Medical Association 286, no. 18 (2001): 2251–2256.
K. A. Phillips et al., “Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers,” Journal of Clinical Oncology 31, no. 25 (2013): 3091–3099.
N. Orr et al., “Fine-Mapping Identifies Two Additional Breast Cancer Susceptibility Loci at 9q31.2,” Human Molecular Genetics 24, no. 10 (May 2015): 2966–2984.
A. C. Antoniou et al., “Common Alleles at 6q25.1 and 1p11.2 Are Associated with Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers,” Human Molecular Genetics 20, no. 16 (2011): 3304–3321.
V. G. Vogel et al., “Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial,” Journal of the American Medical Association 295, no. 23 (June 2006): 2727–2741.
J. Cuzick et al., “Selective Oestrogen Receptor Modulators in Prevention of Breast Cancer: An Updated Meta-analysis of Individual Participant Data,” The Lancet 381, no. 9880 (2013): 1827–1834.
R. T. Chlebowski et al., “Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women,” Journal of Clinical Oncology 28, no. 22 (2010): 3582–3590.
G. Rennert, M. Pinchev, and H. S. Rennert, “Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer,” Journal of Clinical Oncology 28, no. 22 (2010): 3577–3581.
T. J. Hall and M. Schaueblin, “A Pharmacological Assessment of the Mammalian Osteoclast Vacuolar H+-ATPase,” Bone and Mineral 27, no. 2 (1994): 159–166.
M. Bodmer et al., “Long-Term Metformin Use Is Associated with Decreased Risk of Breast Cancer,” Diabetes Care 33, no. 6 (2010): 1304–1308.
R. Govindarajan et al., “Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients with Diabetes,” Journal of Clinical Oncology 25, no. 12 (2007): 1476–1481.
F. Frasca et al., “The Role of Insulin Receptors and IGF-I Receptors in Cancer and Other Diseases,” Archives of Physiology and Biochemistry 114, no. 1 (2008): 23–37; L. L. Lipscombe et al., “The Impact of Diabetes on Survival Following Breast Cancer,” Breast Cancer Research and Treatment 109, no. 2 (2008): 389–395.
A. DeCensi et al., “Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis,” Cancer Prevention Research 3, no. 11 (2010): 1451–1461.
Читать дальше